Ariane Dienst

Sorafenib (Nexavar) induces molecular remission and regression of extramedullary disease in a patient with FLT3-ITD+ acute myeloid leukemia.

I. Bruns, G. Kobbe, R. Fenk, 2009, Leukemia research.

Lenalidomide consolidation treatment in patients with multiple myeloma suppresses myelopoieses but spares erythropoiesis

K. Köhrer, I. Bruns, Ron-Patrick Cadeddu, 2016, International journal of cancer.

Treatment of Poor Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia with a Combination of 5-Azacytidine and Valproic Acid

U. Germing, R. Haas, O. Ottmann, 2008 .

Soluble Tissue Factor Induces Coagulation on Tumor Endothelial Cells In Vivo if Coadministered With Low-Dose Lipopolysaccharides

Andreas Engert, J. Fries, A. Engert, 2003, Arteriosclerosis, thrombosis, and vascular biology.

Specific occlusion of murine and human tumor vasculature by VCAM-1-targeted recombinant fusion proteins.

J. Fries, J. Nör, C. Gottstein, 2005, Journal of the National Cancer Institute.

Sorafenib and azacitidine as salvage therapy for relapse of FLT3‐ITD mutated AML after allo‐SCT

U. Germing, G. Kobbe, R. Haas, 2017, European journal of haematology.